Elicio to advance pancreatic, HPV vaccines, CAR T booster with $33M B round

Six months after raising a $30 million series A round, Elicio has added $33 million via its B round to begin Phase I/II testing of its KRAS-driven cancer vaccine ELI-002 and advance its other immunotherapies.

Elicio Therapeutics’ Amphiphile platform, which attaches antigens to an albumin-binding lipid tail for transport to lymph nodes, was developed by co-founder Darrell Irvine. Irvine is a Massachusetts Institute of Technology professor of materials science and engineering and of biological engineering...